NEW YORK, April 15 (GenomeWeb News) - Celera Genomics announced yesterday that two of its antigen targets have been selected for further investigation by Abbott for cancer therapeutic development.
The targets were developed by Celera Genomics over the last year, since the company signed a collaboration agreement with Abbott to use proteomic technologies to develop cell surface antigens that could serve as cancer therapeutics.
Kathy Ordonez, president of Celera Genomics, said the agreement is "an important milestone" toward the company's goal of developing a pipeline of therapies derived from its proteomics platform.
Financial terms for the agreement were not provided.